As of **April 24, 2026**, the hypotheses that most credibly survive are:
1. **#1 Higher baseline kinase activity more than higher swelling gain**
2. **#4 Amplification is context-dependent and strongest in microglia/macrophages**
3. **#5 `pRab12` may be the better translational biomarker under chronic lysosomal stress**
4. **#6 A downstream `LRRK2-Rab10/JIP4` lysosomal stress to α-syn release loop is plausible**
5. **#2 LYTL/JIP4 remodeling is a useful mechanistic phenotype, but not yet a primary therapeutic thesis**
**#3 phosphatase buffering** survives as an assay-interpretation modifier, not as a realistic near-term drug program.
The key point is that **the druggable node is still LRRK2 kinase**, not Rab12, JIP4, or PPM1H/M today. The main open question is not “what to drug?” but “which biology best predicts benefit, in which cell type, and with which biomarkers?”
**Priority Assessment**
| Idea | Feasibility | Druggability | Biomarker readiness | Trial readiness |
|---|---|---:|---:|---:|
| #1 Baseline floor > gain | High | High via LRRK2 inhibitors | High | High |
| #4 Microglia/phagocyte-selective amplification | High | Indirectly high | Medium-High | Medium |
| #5 Rab12 as chronic-stress biomarker | Medium-High | Low as target, high as biomarker | High exploratory | Medium |
| #6 α-syn feed-forward loop | Medium | High via LRRK2, low via downstream nodes | Medium | Medium-Low |
| #2 LYTL/JIP4 remodeling | Medium | Low-Medium | Medium | Low |
**Per Surviving Idea**
**1. G2019S mainly raises the activity floor**
This is the strongest and most development-relevant interpretation. It fits the neutrophil data where **R1441G is much stronger than G2019S for endogenous pRab10**, and it is consistent with the idea that membrane recruitment is the main activation event while G2019S adds modest catalytic bias rather than a huge gain boost. Sources: [PMID 34125248](https://pubmed.ncbi.nlm.nih.gov/34125248/), [PMID 35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/).
Druggability: high, because it points directly to **partial LRRK2 kinase inhibition**, which is already clinically actionable.
Biomarkers/model systems: use **isogenic WT vs G2019S iPSC-microglia and monocyte-derived macrophages** with graded swelling paradigms; primary readouts should be `pT73-Rab10`, `pS106-Rab12`, `pS1292-LRRK2`, urine BMP, and PBMC phospho-Rab. Avoid overexpression and avoid relying on LLOME alone.
Safety: best-understood among all ideas because it leverages the existing LRRK2 inhibitor path. Main known risks remain **lung type II pneumocyte vacuolation, renal morphology, and immune/host-defense effects**, though preclinical lung/kidney changes were reported as reversible and early BIIB122 studies were generally tolerable. Sources: [PMID 32321864](https://pubmed.ncbi.nlm.nih.gov/32321864/), [PMID 29307545](https://pubmed.ncbi.nlm.nih.gov/29307545/).
Timeline/cost: **12-18 months, $1.5M-$3M** for a decisive preclinical package; if positive, it can feed directly into ongoing LRRK2 clinical biomarker work rather than needing a new drug program.
**4. Amplification is strongest in microglia/macrophages**
This is very plausible biologically and matters for disease mechanism, even if it may not fully explain neuronal vulnerability. Phagocytes clearly have stronger endogenous `LRRK2-Rab10` biology and more relevant lysosomal cargo handling. Sources: [PMID 32853409](https://pubmed.ncbi.nlm.nih.gov/32853409/), [PMID 38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/).
Druggability: still via **LRRK2 inhibition**, not via “microglia-specific volume sensing” per se.
Biomarkers/model systems: strongest systems are **iPSC-microglia**, primary monocyte/macrophage models, and co-cultures with neurons for cargo-transfer effects. This is more informative than dopaminergic monoculture for this specific hypothesis.
Safety: favorable from a translational logic standpoint because microglia/macrophages are likely where on-target pharmacology will be most visible, but that also raises **innate immune suppression / altered trafficking** concerns if inhibition is too deep.
Timeline/cost: **18-24 months, $3M-$5M** for a solid cell-type comparison package with live imaging, cytokines, cargo trafficking, and pharmacology. Good mechanistic program; not by itself a new IND path.
**5. Rab12 may outperform Rab10 as the translational readout**
This is the best biomarker-facing idea. Human PBMC data now support **`pS106-Rab12` elevation in G2019S carriers**, and recent brain pathology data show `pRab12` accumulation in lysosome-like structures across synuclein/tau disease contexts, including G2019S-linked disease. Sources: [PMID 39705401](https://pubmed.ncbi.nlm.nih.gov/39705401/), [PMID 41128923](https://pubmed.ncbi.nlm.nih.gov/41128923/), [PMID 37889931](https://pubmed.ncbi.nlm.nih.gov/37889931/), [PMID 40690364](https://pubmed.ncbi.nlm.nih.gov/40690364/).
Druggability: low as a direct target. `Rab12` is much more useful as a **pharmacodynamic / enrichment biomarker** than as a therapeutic node.
Biomarkers/model systems: PBMC assay development is already realistic. Best package is **paired PBMC + iPSC-microglia time-course** with acute and chronic stress, measuring `pRab12:pRab10` ratio and inhibitor response.
Safety: biomarker-only work is low risk. Therapeutically targeting phosphatases like `PPM1M` or `PPM1H` would be much riskier because these enzymes sit in broad trafficking/ciliogenesis biology.
Timeline/cost: **9-15 months, $1M-$2.5M** for assay qualification and translational bridging. This is the fastest path to something clinically useful.
**6. Feed-forward α-syn release loop**
This is disease-relevant and interesting, but still one inferential step farther from a practical development decision. The macrophage/microglia data support a lysosomal overload to `LRRK2-Rab10` to exosomal α-syn release axis. Source: [PMID 38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/).
Druggability: again strongest at **LRRK2**, not at exosome biology or JIP4 directly.
Biomarkers/model systems: use **PFF-loaded microglia**, conditioned media transfer, exosome fractionation, extracellular α-syn species, and matched viability/lysosomal injury controls. This is a strong secondary package after the baseline-vs-gain question is settled.
Safety: biggest translational risk is that suppressing this loop may also alter normal vesicle trafficking and innate immune handling. The biology is compelling, but not yet specific enough to define a new target.
Timeline/cost: **18-30 months, $4M-$8M** for a serious preclinical package including co-culture and one in vivo propagation model.
**2. LYTL/JIP4 remodeling**
Useful as a mechanistic discriminator, not a primary program. LYTL is real, but the evidence base still leans on acute injury paradigms and imaging-heavy phenotypes. Sources: [PMID 33177079](https://pubmed.ncbi.nlm.nih.gov/33177079/), [PMID 35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/).
Druggability: weak to moderate. `JIP4` is not an attractive conventional small-molecule target today, and disrupting lysosomal tubulation broadly could create toxicity.
Biomarkers/model systems: live-cell imaging of `LAMP1`, `JIP4`, tubule number/duration, and vesicle release is worthwhile as a **secondary mechanistic endpoint**.
Safety: higher uncertainty than kinase inhibition because this pathway is less clinically de-risked.
Timeline/cost: **12-24 months, $2M-$4M**. Good for target validation, poor for standalone translation.
**What I would actually advance**
The best near-term program is:
1. Run the **endogenous dose-response study** in isogenic WT/G2019S microglia and macrophages.
2. Make **`pRab12` and `pRab10` paired biomarkers**, not competitors.
3. Treat **LYTL and α-syn release as downstream discriminators**, not primary theses.
4. Keep the therapeutic strategy centered on **partial LRRK2 inhibition**.
That is the only path here that is both mechanistically clean and developmentally realistic. It also fits the current clinical landscape: **BIIB122** remains in active Phase 2 development, with **LUMA** enrolled and a **Phase 2a LRRK2-PD biomarker study (NCT06602193)** recruiting/ongoing as of **February 18, 2026**. Sources: [ClinicalTrials.gov NCT06602193](https://www.clinicaltrials.gov/study/NCT06602193), [Denali 2026 milestones](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-key-anticipated-milestones-and).
If you want, I can turn this into a strict **go/no-go matrix** with scores for druggability, assayability, patient-selection value, and estimated probability of clinical translation.